Cas no 171440-19-0 ((S)-Rabeprazole Sodium Salt)

(S)-Rabeprazole Sodium Salt is a chiral proton pump inhibitor (PPI) used primarily in the treatment of acid-related gastrointestinal disorders. As the (S)-enantiomer of rabeprazole, it exhibits enhanced metabolic stability and potency compared to the racemic mixture, leading to improved therapeutic efficacy. Its sodium salt form ensures better solubility and bioavailability, facilitating formulation development. This compound selectively inhibits gastric acid secretion by targeting H+/K+-ATPase in parietal cells. Its stereochemical purity minimizes off-target effects, making it a preferred choice for precision medicine applications. (S)-Rabeprazole Sodium Salt is widely utilized in pharmaceutical research and development for its reliable pharmacokinetic profile and consistent performance in acid suppression therapies.
(S)-Rabeprazole Sodium Salt structure
(S)-Rabeprazole Sodium Salt structure
Product Name:(S)-Rabeprazole Sodium Salt
CAS No:171440-19-0
MF:C18H22N3NaO3S
MW:383.44
CID:1063649
PubChem ID:14720269
Update Time:2025-05-26

(S)-Rabeprazole Sodium Salt Chemical and Physical Properties

Names and Identifiers

    • (S)-Rabeprazole Sodium Salt
    • (S)-RABEPRAZOLE
    • (S)-Rabeprazole Sodi
    • Rabeprazolesodium Impurity W
    • HMS2231E04
    • AKOS025310160
    • Q27108142
    • 2-[[[4-(3-Methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]benzimidazole sodium salt
    • 2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridyl)methyl)sulfinyl)benzimidazole sodium salt
    • BR167318
    • rabeprazole sodium delayed-release
    • Idiazole
    • D00724
    • Pariprazole sodium
    • BDBM50247881
    • 117976-90-6
    • 1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, sodium salt
    • sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide
    • AKOS015962116
    • RABEPRAZOLE SODIUM SALT [MI]
    • LY 307640 sodium
    • AC-715
    • RABEPRAZOLE SODIUM (MART.)
    • Monosodium (RS)-2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1H-benzimidazolide
    • Rabeprazole SodiumDR
    • DTXCID1024205
    • DTXSID3044205
    • LY307640 sodium
    • s4665
    • LY-307640
    • 3L36P16U4R
    • CCG-213574
    • RABEPRAZOLE SODIUM [USP-RS]
    • RABEPRAZOLE SODIUM (EP MONOGRAPH)
    • NSC-759270
    • NCGC00159518-05
    • UNII-3L36P16U4R
    • Q-201655
    • Rabeprazole sodium- Bio-X
    • Aciphex Sodium
    • 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, sodium salt (1:1)
    • Aciphex Sprinkle
    • Rabeprazole na
    • sodium 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)benzimidazol-1-ide
    • Tox21_111736
    • NSC 759270
    • MLS006010621
    • Rabeprazole sodium [USAN]
    • Rebeprazole sodium
    • SMR000550493
    • Tox21_302317
    • HY-B0656A
    • Rablet
    • Sodium, Rabeprazole
    • 171440-19-0
    • SR-01000799133
    • Pariet (TN)
    • Dexrabeprazolesodium
    • Aciphex (TN)
    • BCP06639
    • AKOS015895734
    • R0115
    • sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzimidazol-1-ide
    • C07865
    • AS-13338
    • E 3810
    • F17418
    • NCGC00159518-02
    • Rabeprazole (sodium)
    • MFCD02092688
    • Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
    • RABEPRAZOLE SODIUM [ORANGE BOOK]
    • RABEPRAZOLE SODIUM [MART.]
    • CHEMBL1200930
    • RABEPRAZOLE SODIUM [EP MONOGRAPH]
    • HMS3373B05
    • Rabeprazole sodium (JP17/USP)
    • Aciphex
    • Habeprazole Sodium
    • Sodium (S)-2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
    • CAS-117976-90-6
    • CHEBI:8769
    • RABEPRAZOLE SODIUM (USP-RS)
    • Pepcia
    • sodium 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)benzo[d]imidazol-1-ide
    • (Former JAN: Sodium Rabeprazole)
    • LY-307640 SODIUM
    • E3810
    • Sodium rabeprazole
    • RABEPRAZOLE SODIUM [USP MONOGRAPH]
    • EX-A176
    • SR-01000799133-2
    • SCHEMBL140494
    • Rabeprazole sodium salt
    • MLS001165734
    • pariete
    • HMS2093H10
    • RABEPRAZOLE NA [VANDF]
    • RABEPRAZOLE SODIUM
    • sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole
    • Rabeprazole sodium, >=98% (HPLC)
    • CCG-268423
    • RABEPRAZOLE SODIUM [WHO-DD]
    • E-3810 SODIUM
    • Rabicip
    • RABERPRAZOLE SODIUM D/R
    • 2-[[[4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole, Sodium Salt
    • RABEPRAZOLE SODIUM (USP MONOGRAPH)
    • Tox21_111736_1
    • RABEPRAZOLE SODIUM [JAN]
    • J-010726
    • NCGC00255838-01
    • Pariet
    • [2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methylsulfinyl]benzimidazol-1-yl]sodium
    • Inchi： InChI=1S/C18H20N3O3S.Na/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18;/h3-4,6-9H,5,10-12H2,1-2H3;/q-1;+1
    • InChI Key： KRCQSTCYZUOBHN-UHFFFAOYSA-N
    • SMILES： Cc1c(ccnc1CS(=O)c2[n-]c3ccccc3n2)OCCCOC.[Na+]

Computed Properties

  • Exact Mass: 382.12
  • Monoisotopic Mass: 382.12
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 1
  • Hydrogen Bond Acceptor Count: 6
  • Heavy Atom Count: 26
  • Rotatable Bond Count: 8
  • Complexity: 440
  • Covalently-Bonded Unit Count: 2
  • Defined Atom Stereocenter Count: 1
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Topological Polar Surface Area: 96.3A^2

Experimental Properties

  • Density: Not available
  • Melting Point: Not available
  • Boiling Point: Not available
  • Flash Point: Not available
  • Vapor Pressure: Not available

(S)-Rabeprazole Sodium Salt Security Information

(S)-Rabeprazole Sodium Salt Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
TRC
R070525-1mg
(S)-Rabeprazole Sodium Salt
 171440-19-0
1mg
 $ 215.00 2023-09-06
TRC
R070525-10mg
(S)-Rabeprazole Sodium Salt
 171440-19-0
10mg
 $ 1629.00 2023-09-06
SHENG KE LU SI SHENG WU JI SHU
sc-391205-1 mg
(S)-Rabeprazole Sodium Salt, (Out of Stock: Availability 7/28/23)
 171440-19-0
1mg
 ￥2,708.00 2023-07-10
SHENG KE LU SI SHENG WU JI SHU
sc-391205-1mg
(S)-Rabeprazole Sodium Salt,
 171440-19-0
1mg
 ￥2708.00 2023-09-05

(S)-Rabeprazole Sodium Salt Related Literature

Related Categories

Additional information on (S)-Rabeprazole Sodium Salt

Introduction to (S)-Rabeprazole Sodium Salt (CAS No. 171440-19-0)

(S)-Rabeprazole Sodium Salt, with the chemical compound identifier CAS No. 171440-19-0, is a significant pharmaceutical compound that has garnered considerable attention in the field of medicinal chemistry and drug development. This compound is a key intermediate in the synthesis of rabeprazole, a widely used proton pump inhibitor (PPI) that is highly effective in treating gastrointestinal disorders such as gastroesophageal reflux disease (GERD) and peptic ulcer disease.

The< strong>S-configuration of rabeprazole sodium salt is particularly important due to its enhanced pharmacological activity compared to its racemic form. The stereochemical specificity of this compound contributes to its high efficacy and low toxicity profile, making it a preferred choice for therapeutic applications. The sodium salt form of (S)-rabeprazole enhances its solubility and bioavailability, which are critical factors in drug formulation and delivery.

In recent years, there has been a growing interest in the development of novel PPIs that offer improved pharmacokinetic properties and reduced side effects. Research has shown that the< strong>S-enantiomer of rabeprazole exhibits superior binding affinity to the H+/K+-ATPase enzyme, which is the primary target of PPIs. This high affinity results in prolonged inhibition of gastric acid secretion, providing more effective symptom relief for patients suffering from acid-related disorders.

One of the most compelling aspects of (S)-rabeprazole sodium salt is its mechanism of action. Unlike traditional antacids, which provide temporary relief by neutralizing stomach acid, PPIs like rabeprazole work by irreversibly binding to the H+/K+-ATPase pump, thereby reducing the overall production of gastric acid. This mechanism ensures prolonged therapeutic effects, often requiring once-daily dosing for optimal results.

The synthesis and purification of (S)-rabeprazole sodium salt are complex processes that require precise control over reaction conditions and stereochemistry. Advanced chiral resolution techniques, such as enzymatic resolution or diastereomeric salt formation, are commonly employed to isolate the active (S)-enantiomer from racemic mixtures. These techniques ensure high enantiomeric purity, which is essential for pharmaceutical-grade materials.

Recent studies have also explored the potential applications of (S)-rabeprazole sodium salt beyond its traditional uses in GERD and peptic ulcer treatment. For instance, researchers have investigated its role in preventing stress-induced ulcers and protecting the gastric mucosa from damage caused by nonsteroidal anti-inflammatory drugs (NSAIDs). The compound's ability to modulate gastric acid secretion makes it a promising candidate for broader therapeutic applications.

The pharmacokinetic profile of (S)-rabeprazole sodium salt is another area of active research. Studies have demonstrated that this compound exhibits rapid absorption after oral administration, with peak plasma concentrations achieved within 1-2 hours. The bioavailability is significantly enhanced when administered with food, suggesting that co-administration with meals may improve therapeutic outcomes.

From a regulatory perspective, (S)-rabeprazole sodium salt must meet stringent quality standards set by global health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulations ensure that pharmaceutical products are safe, effective, and consistently manufactured to high standards. Compliance with these guidelines is crucial for manufacturers seeking to market their products in major pharmaceutical markets.

The role of computational chemistry and molecular modeling in optimizing the design of (S)-rabeprazole sodium salt cannot be overstated. These tools allow researchers to predict the binding interactions between the compound and its target enzymes with high accuracy. By leveraging computational methods, scientists can identify structural modifications that enhance potency and reduce potential side effects.

In conclusion, (S)-rabeprazole sodium salt (CAS No. 171440-19-0) represents a significant advancement in the treatment of gastrointestinal disorders. Its unique stereochemical configuration, enhanced solubility, and potent pharmacological activity make it a valuable component in modern therapeutics. As research continues to uncover new applications and optimize manufacturing processes, this compound is poised to remain a cornerstone in pharmaceutical innovation.

171440-19-0 ((S)-Rabeprazole Sodium Salt) Related Products

Recommended suppliers
Changzhou Guanjia Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Changzhou Guanjia Chemical Co., Ltd
Hebei Liye chemical Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Hebei Liye chemical Co.,Ltd
PRIBOLAB PTE.LTD
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
PRIBOLAB PTE.LTD
Shenzhen Jianxing Pharmaceutical Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Shenzhen Jianxing Pharmaceutical Technology Co., Ltd.
Yunnanjiuzhen
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Yunnanjiuzhen